Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/28630
Title: | Preventive, predictive, and personalized medicine for effective and affordable cancer care | Authors: | JANSSENS, Jaak Schuster, Klaus Voss, Andreas |
Issue Date: | 2018 | Publisher: | SPRINGER INTERNATIONAL PUBLISHING AG | Source: | EPMA JOURNAL, 9(2), p. 113-123 | Abstract: | Preventive, predictive, and personalized medicine (PPPM) has created a wealth of new opportunities but added also new complexities and challenges. The European Cancer Prevention Organization already embraced unanimously molecular biology for primary and secondary prevention. The rapidly exploding genomic language and complexity of methods face oncologists with exponentially growing knowledge they need to assess and apply. Tissue specimen quality becomes one major concern. Some new innovative medicines cost beyond any reasonable threshold of financial support from patients, health care providers, and governments and risk sustainability for the health care system. In this review, we evaluate the path for genomic guidance to become the standard for diagnostics in cancer care and formulate potential solutions to simplify its implementation. Basically, introduction of molecular biology to guide therapeutic decisions can be facilitated through supporting the oncologist, the pathologist, the molecular laboratory, and the interventionist. Oncologists need to know the exact indication, utility, and limitations of each genomic service. Minimal requirements on the label must be addressed by the service provider. The interventionist is there to bring the most optimal tissue sample to pathology where the tissue is expanded to a variety of appropriate liquid-based samples. The large body of results then should be translated into meaningful clinical guidance for the individual patient. Surveillance, with the appropriate application of health economic indicators, can make this system long lasting. For governments and health care providers, optimal cancer care must result in a cost-effective, resource-sustainable, and patient-focused outcome. | Notes: | [Janssens, Jaak Ph.] European Canc Prevent Org, Klein Hilststr 5, B-3500 Hasselt, Belgium. [Schuster, Klaus; Voss, Andreas] Caris Life Sci, St Jakobsstr 199, CH-4052 Basel, Switzerland. | Keywords: | Predictive preventive personalized medicine; Molecular biology; Patient selection; Cancer care; Biopsy Genomic profiling; Health economics;Predictive preventive personalized medicine; Molecular biology; Patient selection; Cancer care; Biopsy Genomic profiling; Health economics | Document URI: | http://hdl.handle.net/1942/28630 | ISSN: | 1878-5077 | e-ISSN: | 1878-5085 | DOI: | 10.1007/s13167-018-0130-1 | ISI #: | 000433378900001 | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
janssens2018.pdf Restricted Access | Published version | 1.09 MB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
22
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
47
checked on Oct 14, 2024
Page view(s)
132
checked on Sep 7, 2022
Download(s)
94
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.